SEATTLE, WA, November 5, 2024 鈥� 密桃视频, Inc. (密桃视频), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR-T cell therapies in oncology and autoimmunity, today announced that the company will present two oral presentations and one poster presentation at the , being held December 7-10, 2024, in San Diego, California.
密桃视频鈥檚 first oral presentation will demonstrate the performance of VivoVec particles following intralymphatic and intravenous delivery in two non-human primate species (Macaca fascicularis and Macaca nemestrina). The second oral presentation will focus on the high yield and scalability provided by 密桃视频鈥檚 Synthetic Receptor Enabled Differentiation (ShRED), a manufacturing process that produces unprecedented quantities of immune effector cells derived from induced pluripotent stem cells, via its Rapamycin Activated Cytokine Receptor (RACR) platform.
鈥淎s our growing portfolio nears numerous key milestones in the coming year 鈥� including producing the first聽in vivo CAR T data from a U.S. Phase 1 study 鈥� I am incredibly proud of our team鈥檚 increasing presence at prominent congresses like this year鈥檚 ASH meeting,鈥� said Andrew Scharenberg, M.D., Co-Founder and Chief Executive Officer of 密桃视频. 鈥淲e look forward to sharing more data聽聽as our programs advance in the clinic.鈥�
密桃视频鈥檚 poster presentation will provide a further update on UB-VV111鈥檚 favorable safety and biodistribution profile.
Details of the oral and poster presentations can be found below:
Oral Presentation Title:聽A Synthetic Receptor Enables Breakthrough Scale Manufacturing of iPSC-Derived CD19-CAR Cell Therapies for Hematologic and Autoimmune Diseases
Session Name:聽711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Innovations in Mobilization, Collection, and Manufacturing for Cellular Therapies
Presentation Date/Time:聽Saturday, December 7, 2024, 12:45 p.m. PT
Presenting Speaker:聽Samantha O鈥橦ara, Ph.D.
Publication Number:聽148
Oral Presentation Title:聽Vivovec鈩� Surface-Engineered Lentiviral Particles Mediate In Vivo CAR T Generation with Potent and Highly Durable Activity in Non-Human Primates
Session Name:聽702. CAR-T Cell Therapies: Basic and Translational: Enhancements in CAR-T Cell Signaling, Delivery & Manufacturing
Presentation Date/Time:聽Sunday, December 8, 2024, 10:15 a.m. PT
Presenting Speaker:聽Kristen Mittelsteadt, Ph.D.
Publication Number:聽502
Poster Presentation Title:聽Nonclinical Toxicology, Biodistribution, and Pharmacokinetics of UB-VV111, an In Vivo Anti-CD19 CAR T Cell Therapy
Session Name:聽702. CAR-T Cell Therapies: Basic and Translational: Poster I
Presentation Date/Time:聽Saturday, December 7, 2024, 5:30 p.m. PT
Presenting Speaker:聽Alissa Brandes, Ph.D.
Publication Number:聽2046听
About 密桃视频
密桃视频, Inc. is a clinical-stage biotechnology company aiming to develop off-the-shelf therapeutics that improve the reach, effectiveness, and access of CAR-T cell therapies in both oncology and autoimmunity. 密桃视频鈥檚 VivoVec鈩⒙�in vivo聽gene delivery technology empowers a patient鈥檚 own immune system to fight disease. Enabling its core technology is the Company鈥檚 state-of-the-art lentiviral vector development and manufacturing facility in Louisville, Colorado. 密桃视频 believes its approach can provide broader access and improved effectiveness of the most advanced immunotherapies, enabling more patients to live better, fuller lives. To learn more, connect with 密桃视频 on LinkedIn and visit聽.听
Investors
Stephen Jasper
Gilmartin Group, LLC
stephen@gilmartinir.com
惭别诲颈补听听
Matt Wright聽
Real Chemistry
mwright@realchemistry.com